Skip to main content
SpringerLink
Log in

Nebenwirkungen durch die Pharmakotherapie

Renaissance der Phytotherapeutika beim benignen Prostatasyndrom

  • Titel
  • Published:
Geriatrie-Report

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© A. Wiedemann

Abb. 2

© A. Hassenstein (mit freundlicher Genehmigung von Frau PD Dr. A. Hassenstein, Hamburg)

Literatur

  1. Berges RR, Windeler J, Trampisch HJ, Senge T. 1995. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345:1529-32.

  2. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I. 1997. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol. Exp. Ther 282:228-35.

  3. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P. 1996. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29:155-67.

  4. Biaggioni I. 2018. Orthostatic Hypotension in the Hypertensive Patient. Am J Hypertens 31:1255-9.

  5. Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, et al. 2015. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ 351:h5398.

  6. Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. 2018. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 27:340-8.

  7. Tae BS, Jeon BJ, Choi H, Cheon J, Park JY, Bae JH. 2019. alpha-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. J Urol 202:362-8.

  8. Haridas A, Syrimi M, Al-Ahmar B, Hingorani M. 2013. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates. Graefes Arch Clin Exp Ophthalmol 251:1541-5.

  9. Lunacek A, Mohamad Al-Ali B, Radmayr C, Weber M, Horninger W, et al. 2018. Ten years of intraoperative floppy iris syndrome in the era of alpha-blockers. Cent European J Urol 71:98-104.

  10. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, et al. 1996. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47:159-68.

  11. Matsukawa Y, Takai S, Majima T, Funahashi Y, Sassa N, et al. 2019. Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. World J Urol 37:867-72.

  12. Lucas MG, Stephenson TP, Nargund V. 2005. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU. Int 95:354-7.

Download references

Author information

Authors and Affiliations

  1. Ev. Krankenhaus im Diakoniewerk Ruhr Witten gGmbH, Pferdebachstr. 27-43, 58455, Witten, Germany

    Andreas Wiedemann

Authors
  1. Andreas Wiedemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wiedemann, A. Renaissance der Phytotherapeutika beim benignen Prostatasyndrom. Geriatr Rep 16, 33–35 (2021). https://doi.org/10.1007/s42090-021-1265-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42090-021-1265-0

Search

Navigation